)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
AC Immune
AC Immune (ACIU) investor relations material
AC Immune Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary4 Nov, 2026
Executive summary
ACI-7104 reported positive Part 1 week-100 safety and immunogenicity results in Phase 2 VacSYn; the program also received FDA Fast Track designation and IND clearance.
A lead Morphomer small-molecule candidate targeting alpha-synuclein was selected and entered preclinical development; ACI-19764 Phase 1 results showed safety, tolerability and CSF penetration.
Financial highlights
Q3 2026 revenue was CHF 3.244M vs CHF 0.939M in Q3 2025, reflecting Takeda arrangement revenue, including additional consideration for the AD4 Cohort.
Q3 R&D expense was CHF 9.853M vs CHF 13.071M; lower personnel, operational and discovery/preclinical spending partly offset a CHF 1.0M net increase in clinical program costs.
Q3 G&A expense was CHF 3.522M vs CHF 3.567M; operating loss narrowed to CHF 9.801M from CHF 16.166M, and net loss narrowed to CHF 8.750M from CHF 15.858M.
9M 2026 revenue was CHF 19.476M vs CHF 3.235M; operating loss was CHF 23.397M vs CHF 54.924M, and net loss was CHF 21.678M vs CHF 56.074M.
Outlook and guidance
Cash resources are expected to fund operations into Q1 2028, excluding potential milestone payments.
ACI-7104 antibody characterization, including alpha-synuclein binding properties, was anticipated before year-end 2026; FDA discussions on the future development path were planned for early 2027.
Initial ACI-19764 Phase 1b results in patients with elevated hsCRP were expected in early 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from AC Immune
- Pipeline expansion and 2022 readouts ahead, alongside a CHF 73.0M net loss.ACIU
Q4 2021 - Pipeline milestones advanced as CHF 122.6m in liquidity extended runway into Q3 2024.ACIUQ4 2022
- 2024 clinical readouts could de-risk the pipeline, with cash runway into Q1 2026.ACIUQ4 2023
- VacSYn results support advancing ACI-7104 into an expanded Phase 2 study.ACIUInvestor presentation
- Advanced neurodegeneration pipeline and major pharma deals drive strong growth prospects.ACIUInvestor presentation
- ACI-7104 met safety and immunogenicity endpoints, advancing toward larger Parkinson’s testing.ACIUStudy result
- Milestone payments boosted revenue and extended cash runway, with major clinical results ahead.ACIUQ2 2026
- Precision prevention pipeline advances with strong clinical data and major pharma partnerships.ACIUInvestor presentation
- Milestone payments and clinical progress support improved financials and outlook for 2026.ACIUQ1 2026
Next AC Immune earnings date
Q4 202612 Mar, 2027
AC Immune
Next AC Immune earnings date
Q4 202612 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
AC Immune SA is a clinical-stage biopharmaceutical company that specializes in precision medicine for neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and NeuroOrphan diseases. These candidates target the misfolded proteins associated with these diseases, aiming to diagnose, treat, and prevent neurodegeneration. AC Immune SA is headquartered in Lausanne, Switzerland, and its shares are listed on the Nasdaq.